Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

ClinicalTrials.gov ID: NCT00078585

Public ClinicalTrials.gov record NCT00078585. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOM™ in Combination With GM-CSF in Patients With Androgen-Independent Adenocarcinoma of the Prostate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PROSTVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the immune system can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells. These targets are called Tumor Associated Antigens, or TAA's. This trial will help determine if this vaccine can help fight cancer. This multi-center, double-blind, randomized, empty vector-controlled trial is designed to evaluate the safety and efficacy of PROSTVAC-VF/TRICOM co-administered with GM-CSF versus the empty viral vector co-administered with placebo in the treatment of patients with androgen-independent prostate cancer (AIPC). All patients will be required to sign an informed consent prior to the performance of any on-study procedures. Patients will be screened for eligibility within 14 days prior to vaccine administration. Patients who meet all inclusion and exclusion criteria will be centrally randomized into the study and will receive a unique patient identification number and a blinded treatment assignment. The ratio of active treatment to empty vector control (placebo) is 2:1.

Study identification

NCT ID
NCT00078585
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bavarian Nordic
Industry
Enrollment
120 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2003 (Type not available)
Primary completion
Jan 4, 2006 (Actual)
Completion
Jan 2009 (Actual)
Last update posted
Sep 11, 2017

2003 – 2009

United States locations

U.S. sites
47
U.S. states
28
U.S. cities
44
Facility City State ZIP Site status
Urology Centers of Alabama Homewood Alabama 35209 —
Alaska Clinical Research Center Anchorage Alaska 99508 —
Urology Associates of Central California Fresno California 93720 —
San Diego Urology Center La Mesa California 91942 —
Loma Linda University Loma Linda California 92354 —
Atlantic Urology Medical Group Long Beach California 90806 —
Pacific Clinical Research Santa Monica California 90404 —
Western Clinical Research, Inc. Torrance California 90505 —
UCHSC Anschutz Cancer Pavilion Aurora Colorado 80010 —
Connecticut Clinical Research Center Waterbury Connecticut 06708 —
Georgetown University Medical Center Washington D.C. District of Columbia 20007 —
Washington Hospital Center Washington D.C. District of Columbia 20010 —
South Florida Medical Research Aventura Florida 33180 —
Advanced Research Institute New Port Richey Florida 34652 —
Midtown Urology Atlanta Georgia 30308 —
North Idaho Urology Coeur d'Alene Idaho 83814 —
Prairie Medical Associates, Ltd. Chicago Illinois 60616 —
Medical and Surgical Specialists Galesburg Illinois 61401 —
OSF Saint Francis Medical Center Peoria Illinois 61637 —
Carle Clinic Cancer Center Urbana Illinois 61801 —
Metropolitan Urology Jeffersonville Indiana 47130 —
Urologic Associates, PC Davenport Iowa 52807 —
Franklin Square Hospital Center Baltimore Maryland 21237 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 —
University of Nebraska Medical Center Omaha Nebraska 68198-7680 —
Lawrenceville Urology Lawrenceville New Jersey 08648 —
The Cancer Institute of New Jersey New Brunswick New Jersey 08903 —
Urology Group of New Mexico Albuquerque New Mexico 87109 —
The Urological Institute of Northeastern New York Albany New York 12208 —
AccuMed Research Associates Garden City New York 11530 —
Columbia Presbyterian Medical Center New York New York 10032 —
Nyack Hospital Nyack New York 10960 —
The Urology Center Greensboro North Carolina 27403 —
University of Pittsburgh Pittsburgh Pennsylvania 15232 —
Charleston Cancer Center Charleston South Carolina 29406 —
Urology Associates Clinical Research Nashville Tennessee 37209 —
Arlington Cancer Center Arlington Texas 76012 —
Urology Clinic of North Texas, PA Dallas Texas 75231 —
Texas Cancer Center Fort Worth Texas 76104 —
Texas Cancer Care Weatherford Texas 76086 —
Salt Lake Research Salt Lake City Utah 84124 —
University of Vermont South Burlington Vermont 05403 —
Virginia Urology Center Richmond Virginia 23235 —
McGuire Research Institute Richmond Virginia 23249 —
Midwest Research Specialists, LLC Milwaukee Wisconsin 53209 —
Medical College of Wisconsin Milwaukee Wisconsin 53226 —
Wyoming Research Foundation, Inc. Cheyenne Wyoming 82001 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00078585, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 11, 2017 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00078585 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →